Stockreport

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event [Yahoo! Finance]

OKYO Pharma Limited - American Depositary Shares  (OKYO) 
PDF innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neurop [Read more]